Undisclosed Bi-specific/Multi-specific Programs
Oncology
PreclinicalActive
Key Facts
About SystImmune
SystImmune is a private, preclinical-stage biotech focused on next-generation antibody therapeutics for oncology. The company leverages a platform for designing bi-specific, multi-specific antibodies and ADCs aimed at improving tumor targeting and immune system engagement. As a pre-revenue entity, its success hinges on advancing its pipeline through clinical validation and securing strategic partnerships or further investment. The competitive but high-reward oncology market presents a significant opportunity if its technology demonstrates superior efficacy or safety.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Bi-XDC with PROTACs | Coherent Biopharma | IND-enabling |
| Bi-XDC with RPT | Coherent Biopharma | Early-stage |
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Preclinical Projects | Zion Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| XEMA Tumor Marker ELISA Kit | XEMA Group | Commercial |
| KRAS inhibitor | Risen Pharma Tech | Preclinical/Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |